Paxillin participates in MAPK and PI3K/AKT signaling pathways

Paxillin participates in MAPK and PI3K/AKT signaling pathways. Paxillin is transferred to the nucleus through the MAPK pathway and promotes the combination of nuclear ERK and ELK1 to activate the expression of cyclin D1. Paxillin can also affect tumor cell EMT through the ERK signaling pathway. MC-LR promotes paxillin phosphorylation through the MAPK pathway. Ropivacaine reduces the activity of small GTPases, thereby inhibiting the MAPK/JNK signaling pathway to reduce the phosphorylation level of paxillin. GDP-9 promotes paxillin expression and paxillin phosphorylation through Smad-dependent pathways. CX-4945 can reduce paxillin expression and paxillin phosphorylation by inhibiting the TGF-β signaling pathway. Hesperetin can inhibit TGF-β-mediated Fyn activation by reducing paxillin phosphorylation to inhibit RhoA expression and rock activation, which affects tumor migration and invasion. IGF-IR increases paxillin phosphorylation by activating Akt and MAPK signaling cascades. PTPRT can dephosphorylate paxillin tyrosine-88 residue to inhibit the PI3K/AKT pathway and thus inhibit tumorigenesis. P50 and P65 can regulate the transcription and expression of paxillin, and PTEN can reduce the expression of paxillin by dephosphorylating PIP3 to inhibit the PI3K/AKT/NF-κB pathway

Publication

The Role of Paxillin Aberrant Expression in Cancer and Its Potential as a Target for Cancer Therapy (2023) Weixian Liu, et al. Int J Mol Sci. 2023 May;24(9). Figure: F3. Homo sapiens

Disease mentions